Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;24(4):681-692.
doi: 10.1007/s12094-022-02806-x. Epub 2022 Mar 23.

SEOM-GECOD clinical guideline for unknown primary cancer (2021)

Ferrán Losa #  1 , Isaura Fernández #  2 , Olatz Etxaniz #  3 , Alejandra Giménez #  4 , Paula Gomila #  5 , Lara Iglesias #  6 , Federico Longo #  7 , Esteban Nogales #  8 , Antonio Sánchez #  9 , Gemma Soler #  10
Affiliations

SEOM-GECOD clinical guideline for unknown primary cancer (2021)

Ferrán Losa et al. Clin Transl Oncol. 2022 Apr.

Abstract

Cancer of unknown primary site (CUP) is defined as a heterogeneous group of tumors that appear as metastases, and of which standard diagnostic work-up fails to identify the origin. It is considered a separate entity with a specific biology, and nowadays molecular characteristics and the determination of actionable mutations may be important in a significant group of patients. In this guide, we summarize the diagnostic, therapeutic, and possible new developments in molecular medicine that may help us in the management of this unique disease entity.

Keywords: Cancer; Diagnosis; Treatment; Unknown primary site.

PubMed Disclaimer

Conflict of interest statement

Ferran Losa: Advisory or Consultancy: Roche, Amgen; Speaker Bureau: Roche, Amgen,Merck, Sanofi, Servier and Travel/Accommodation or Expenses: Roche, Amgen,Merck, Sanofi. Isaura Fernandez. Consultant or Advisory: Roche, Astra Zeneca; Speaker Bureau: Pfizer, AstraZeneca, Roche,MSD, Clovis,Glaxo. Olatz Etxaniz. Consultant or Advisory: Pfizer, Merck,Ipsen,Roche; Speaker Bureau: Pfizer,Ipsen,BMS; Expenses: Clovis, Pfizer,Janssen,BMS. Alejandra Giménez. Consultant or Advisory: Ipsen; Speaker Bureau: Merck, Ipsen, Sanofi; Expenses: Merck, Amgem, Roche. Paula Gomila. No disclosures. Lara Iglesias. Consultant or Advisory: Merck, MSD, BMS, Lilly, Roche, Bayer, Sanofi. Speaker Bureau: Merck, MSD, BMS, Roche, Bayer, Sanofi, Eisai, Kyowa-kirin. Federico Longo. Advisory/Consultant: Roche, Ferre. Esteban Nogales. Consultant or Advisory: Roche, Daiichi Sankyo; Speaking: Pfizer, AstraZeneca, Roche, Kyowa Kirin. Antonio Sánchez: No disclosures. Gemma Soler. Advisory or Consultancy: Amgem,Roche,Kiowa; Speaker Bureau: Amgem,Merck,Roche, Sanofi, Servier and Travel/Accommodation or Expenses: Amgem, Merck,Roche, Sanofi.

Figures

Fig. 1
Fig. 1
CK 7/CK 20 profile and additional markers. ( Adapted from J Gastrointestin Liver Dis, 2017 (26).1:69–79
See this image and copyright information in PMC

References

    1. Dykewicz CA. Centers for Disease Control and Prevention (U.S.), infectious diseases society of America, American society of blood and marrow transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33(2):139–144. - PubMed
    1. Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. 2019;61:139–141. - PubMed
    1. Conway A-M, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’. Br J Cancer. 2019;120(2):141–153. - PMC - PubMed
    1. Rassy E, Assi T, Pavlidis N. Exploring the biological hallmarks of cancer of unknown primary: where do we stand today? Br J Cancer. 2020;122(8):1124–1132. - PMC - PubMed
    1. Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol. 2009;11(6):340–348. - PubMed

MeSH terms